糖氨基氨基甘油在糖尿病药物治疗中的分子含义
Tanya Waseem1, Madiha Ahmed1, Tausif Ahmed Rajput1
1Department of Pharmaceutical Chemistry, Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad 44000, Pakistan.
International journal of biological macromolecules
|July 19, 2023
概括
葡萄糖氨基甘油 (GAG) 在糖尿病并发症中至关重要. 这篇综述探讨了GAG.
科学领域:
- 生物化学和分子生物学
- 内分泌学和新陈代谢学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 糖尿病导致广泛的代谢障碍和器官损伤.
- 糖尿病的微血管和宏血管并发症与基底膜中的糖氨基糖 (GAG) 损伤有关.
- 负电荷的多糖体GAG对于细胞过程和细胞外基质完整性至关重要.
研究的目的:
- 审查糖氨基 (GAG) 在糖尿病中的作用.
- 探索GAG蛋白相互作用作为糖尿病并发症的潜在治疗点.
- 讨论GAG在糖尿病管理中的诊断和治疗潜力.
主要方法:
- 审查关于糖氨基氨基甘 (GAG) 和糖尿病的现有文献.
- 对与糖尿病并发症相关的GAG蛋白相互作用的分析.
- 对基于GAG的药物的药物化学和临床药理疗学的检查.
主要成果:
- GAG在细胞增殖和信号传导中发挥着重要作用.
- 对GAG的损伤有助于器官损伤,包括心肌纤维化,视网膜病变和病变.
- GAG-蛋白相互作用为治疗糖尿病并发症提供了潜在的点,GAG也可以作为生物标志物.
结论:
- 葡萄糖氨基甘 (GAG) 涉及到糖尿病及其并发症的发病.
- 基于GAG的疗法在诊断,管理和预防糖尿病及其后果方面表现有前途.
- 对GAG的药用化学和药理疗学的进一步研究是有必要的,以建立基于GAG的治疗方法.
相关概念视频
Glycosaminoglycans
4.9K
Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are long and linear polymers comprising of specific repeating disaccharides - the amino sugar that can be N-acetylglucosamine or N-acetylgalactosamine, and a uronic acid that is usually glucuronic acid or iduronic acid.
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
4.9K
Proteoglycans
3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
Protein Glycosylation
7.0K
Glycosylation, the most common post-translational modification for proteins, serves diverse functions. Adding sugars to proteins makes the proteins more resistant to proteolytic digestion. Glycosylated proteins can act as markers and receptors to promote cell-cell adhesion. Additionally, they have many essential quality control functions in the cell, such as correct protein folding and facilitating transport of misfolded proteins to the cytosol, which can be degraded.
Glycosylation occurs in...
Glycosylation occurs in...
7.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234


